Pharmaceuticals

SC Pharmaceuticals

SC Pharmaceuticals released FY2025 Q3 earnings on October 29 Pre-Market BJT, actual revenue CNY 84.78 M, actual EPS CNY 0.0387

SC Pharmaceuticals released FY2025 9 Months earnings on October 29 Pre-Market (BJT), actual revenue CNY 168.9 M, actual EPS CNY -0.0057

SC Pharmaceuticals to Release FY2025 Q3 Earnings Report on October 30 Pre-Market BJT

SC Pharmaceuticals released FY2025 Q2 earnings on July 30 Pre-Market (BJT), actual revenue CNY 47.45 M, actual EPS CNY -0.0203

SC Pharmaceuticals released FY2025 Semi-Annual earnings on July 30 Pre-Market (BJT), actual revenue CNY 84.12 M, actual EPS CNY -0.0445

SC Pharmaceuticals FY2025 Semi-Annual Earnings Release on July 31, 2025 (BJT)

*ST Shuang Cheng Announces 2025 H1 Earnings Forecast

*ST Shuang Cheng Expected to Report Net Loss of RMB 13 to 19 Million for H1 2025

*ST Shuang Cheng's Injectable Paclitaxel Receives FDA Approval for Market Access

Shuang Cheng Obtains Market Authorization for Eptifibatide Injection in Australia

*ST DoubleWin's Albumin-bound Paclitaxel Injection Receives FDA Marketing Approval

*ST Shuang Cheng Holds Earnings Briefing to Outline Future Development Strategies

*ST Shuang Cheng Obtained Australian Market Approval for Injectable Bivalirudin

Changhe Pharmaceutical Announced Q1 2025 Earnings Report

SC Pharmaceuticals released FY2024 Annual Earnings on April 28 After-Market (BJT), Actual Revenue: CNY 174.21 M, Actual EPS: CNY -0.19

SC Pharmaceuticals released FY2024 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 47.25 M, actual EPS CNY -0.0998

SC Pharmaceuticals released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 36.68 M, actual EPS CNY -0.0242

Shuang Cheng Pharmaceutical Surges to Daily High During Trading Session

SC Pharmaceuticals to Release FY2025 Q1 Earnings on April 29 After-Market BJT

SC Pharmaceuticals to Release FY2024 Earnings Report on April 29 After-Market BJT

艾力斯

兴齐眼药

恒瑞医药

云南白药

信立泰

海思科

华润三九

同仁堂

凯莱英

东阿阿胶

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap